阿巴诺喹甲磺酸盐 | 118931-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 阿巴诺喹甲磺酸盐
• 中文别名: 阿巴诺喹
• 英文名称: 4-Amino-6,7-dimethoxy-2-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)quinoline methanesulfonate
• 英文别名: 2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxyquinolin-4-amine;methanesulfonic acid
• CAS: 118931-00-3
• 化学式: C23H29N3O7S
• 分子量: 491.6
• InChiKey: FMDPOTBKJNHQLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.92
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  142
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-[1-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-eth-(E)-ylideneamino]-4,5-dimethoxy-benzonitrile 以48的产率得到阿巴诺喹甲磺酸盐
  参考文献：
  名称：

  Tetrahedron Letters 1984, 25, 4813-4816

  摘要：

  DOI：

文献信息

• Treatment of BPH with cGMP elevators
  申请人：Pfizer Products Inc.

  公开号：EP1020190A2

  公开（公告）日：2000-07-19

  BPH in human males, unstable bladder contractions in human females, and LUTS in both males and females can be treated by orally administering an effective amount of a cGMP PDE inhibitor to a patient in need of such treatment. The cGMP PDE inhibitor can be co-administered with an α-adrenergic antagonist. When a combination of a cGMP PDE inhibitor and an α-adrenergic antagonist are administered, they can be administered together in a composition or administered separately. If administered separately, they can be embodied in a kit.

  通过向需要治疗的患者口服有效量的 cGMP PDE 抑制剂，可以治疗男性良性前列腺增生症、女性不稳定的膀胱收缩以及男性和女性的尿失禁。cGMP PDE 抑制剂可与α-肾上腺素能拮抗剂联合使用。当 cGMP PDE 抑制剂和 α-肾上腺素能拮抗剂联合给药时，它们可以在组合物中一起给药，也可以分开给药。如果分开给药，则可将其制成试剂盒。
• Pharmaceutical combinations for treating lower urinary tract disfunctions
  申请人：Pfizer Products Inc.

  公开号：EP1123705A1

  公开（公告）日：2001-08-16

  This invention relates to pharmaceutical combinations suitable for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia in men, which combinations contain- an alpha-adrenoceptor antagonist and a muscarinic antagonist. The combinations of the invention are particularly suitable for treating moderate or severe lower urinary tract symptoms.

  本发明涉及适用于治疗与男性良性前列腺增生症相关的下尿路症状的药物组合，这些组合含有α-肾上腺素受体拮抗剂和毒蕈碱拮抗剂。本发明的复方制剂尤其适用于治疗中度或重度下尿路症状。
• Pharmaceutical combinations
  申请人：——

  公开号：US20010044438A1

  公开（公告）日：2001-11-22

  Pharmaceutical combinations suitable for treating the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men are described herein. The combinations contain an alpha-adrenoceptor antagonist and a muscarinic antagonist that may be administered simultaneously, separately or sequentially. The methods of treatment using the combinations are particularly suitable for treating moderate or severe LUTS.

  本文描述了适用于治疗与男性良性前列腺增生症（BPH）相关的下尿路症状（LUTS）的药物组合。这些复方制剂包含一种α-肾上腺素受体拮抗剂和一种毒蕈碱拮抗剂，可同时、分别或依次给药。使用这些组合物的治疗方法尤其适用于治疗中度或重度尿失禁。
• Combination effective for the treatment of impotence
  申请人：——

  公开号：US20030040514A1

  公开（公告）日：2003-02-27

  This invention relates to the treatment of erectile dysfunction with a combination of (1) a compound selected from &agr;-adrenergic receptor antagonists, and (2) a compound selected from agents which elevate cGMP levels. Sildenafil or a pharmaceutically acceptable salt thereof is preferred as the cGMP PDE elevator. Also included are compositions and kits comprising such impotence treating compounds.

  本发明涉及(1)选自&agr;-肾上腺素能受体拮抗剂的化合物和(2)选自提高cGMP水平的制剂的化合物的组合治疗勃起功能障碍。首选西地那非或其药学上可接受的盐作为 cGMP PDE 提升剂。此外，还包括含有此类阳痿治疗化合物的组合物和试剂盒。
• COMBINATION OF ALPHA-1-ADRENERGIC ANTAGONISTS AND A CGMP PDEv INHIBITOR FOR THE TREATMENT OF IMPOTENCE
  申请人：Pfizer Products Inc.

  公开号：EP1037616B1

  公开（公告）日：2006-03-01